Langue:

Vous quittez Lundbeck Suisse

Vous quittez maintenant lundbeck.com/ch. Veuillez noter que les informations de la page vers laquelle vous êtes redirigé peuvent ne pas être entièrement conformes aux exigences légales en Suisse, et que les informations relatives aux produits peuvent ne pas être entièrement conformes à l'information professionnelle suisse correspondante pour les médicaments. Toutes les informations doivent être discutées avec votre médecin et ne remplacent pas les conseils et le traitement de votre médecin.

elles sont transmises à

arrière

Pipeline

Nouveaux développements

Notre département de recherche et développement cherche et découvre de nouveaux points de départ pour lutter contre les maladies du cerveau. Ensemble, nous travaillons à l'objectif de fournir aux patients des thérapies qui redéfinissent l'état du traitement et améliorent les soins là où le besoin est le plus grand. 
Projet Domaine Phase 1 Phase 2 Phase 3 Dépôt
Eptinezumab (anti-CGRP mAb) Migraine prevention Filing

Mot d'action

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Eptinezumab (anti-CGRP mAb) Episodic cluster headache 3

Mot d'action

Eptinezumab is a monoclonal immunoglobulin G1 (IgG1) antibody that binds to human calcitonin gene-related peptide (CGRP) with high specificity and high affinity for the CGRP α- and β-form. CGRP is a signaling molecule in the pathophysiology of migraine and cluster headache.

Brexpiprazole* Agitation in Alzheimer's disease 3

Mot d'action

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonin, dopamine, and noradrenaline neurotransmitter systems may be implicated in behavioral symptoms of dementia, including agitation.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Brexpiprazole* PTSD 3

Mot d'action

Brexpiprazole is a small molecule and a potent serotonin–dopamine activity modulator. It acts as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A and noradrenaline α1B/α2C receptors. The serotonergic, dopaminergic, and especially the noradrenergic systems are believed to be involved in PTSD (post-traumatic stress disorder) symptomatology with re-experiencing, Negative cognition and mood, Avoidance and Arousal.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Aripiprazole 2-month injectable* Schizophrenia + Bipolar I disorder 1

Mot d'action

Aripiprazole is a small molecule. It acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and antagonist at serotonin 5-HT2A receptors. A 2-month formulation will serve as a treatment option when treating patients with Schizophrenia or Bipolar I disorder where long-acting treatment is needed.

*Life cycle management. In partnership with Otsuka Pharmaceutical Development & Commercialization, Inc.

Lu AG06466 (MAGL inhibitor) PTSD, MS spasticity 1

Mot d'action

Lu AG06466 is a small molecule and a highly selective inhibitor of monoacylglycerol lipase (MAGL), the primary enzyme responsible for the degradation of the endocannabinoid ligand 2-arachidonoylglycerol (2-AG). Enhancing the actions of 2-AG on CB1 and CB2 receptors may restore altered neuronal transmission and decrease neuroinflammation and thereby it may produce beneficial effects across a range of symptoms and related indications including post-traumatic stress disorder (PTSD), focal epilepsy, and spasticity in patients with multiple sclerosis (MS).

* PTSD, focal epilepsy, and MS spasticity Ph1b studies have been initiated.

Lu AF82422 (anti-alpha-synuclein mAb) Multiple system atrophy 2

Mot d'action

Lu AF82422 is a monoclonal antibody (mAb) targeting alpha-synuclein. Misfolding, aggregation and extracellular spreading of alpha-synuclein is believed to play a major role in disease pathology and progression in Multiple System Atrophy (MSA), Parkinson’s disease and other neurodegenerative disorders.

Lu AF28996 (D1-D2 agonist) Parkinson's disease 1

Mot d'action

Lu AF28996 is a small molecule with agonistic properties towards D1 and D2 receptors. Concerted D1 and D2 dopamine receptor stimulation may play an important role in motor control of Parkinson’s disease patients.

Lu AG09222 (anti-PACAP mAb) Migraine prevention 2

Mot d'action

Lu AG09222 is an investigational monoclonal antibody designed to bind and inhibit signaling mediated by pituitary adenylate cyclase-activating polypeptide (PACAP); a neuropeptide that is implicated in migraine pathophysiology.

Lu AF87908 (anti-Tau mAb) Tauopathies 1

Mot d'action

Lu AF87908 is a monoclonal antibody (mAb) targeting the pathological form of the protein tau which is believed to play a pivotal role in the development and progression of Alzheimer’s disease and other neurodegenerative disorders.

Plus de Lundbeck

Recherche et développement

La R&D de traitements nouveaux et améliorés est au cœur de notre activité.

Carrières

Franchissez une nouvelle étape dans votre carrière avec Lundbeck.

Comprendre les maladies du cerveau

Le voyage vers la santé du cerveau commence par la compréhension des maladies du cerveau.